Pfizer Weighing FDA Request to Change Zoloft's WarningsBy and
FDA suggests altering warnings on congenital cardiac defects
Pfizer faces hundreds of lawsuits over the antidepressant
The U.S. Food and Drug Administration wants Pfizer Inc. to modify safety warnings for its antidepressant Zoloft and acknowledge for the first time that some studies linked the mood-altering medication to heart defects in newborns. The body of evidence on the drug still finds no tie to birth defects.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.